AGP Executive Report
Last update: 11 hours agoBiotech Momentum: Merck just cleared another regulatory hurdle in Europe: the EU’s CHMP issued a positive opinion for KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin) for cisplatin-ineligible adults with resectable muscle-invasive bladder cancer, with a final European Commission decision expected in Q3 2026—covering EU, Iceland, Liechtenstein and Norway. Rare Disease Access: Pharming also won EU marketing authorization for Joenja (leniolisib), the first approved treatment for APDS, with Germany launches expected in Q3 2026. Diplomacy & Trade: India’s Nordic push in Oslo is turning into a green-tech and innovation partnership theme, while Norway is also seeking a seat in EU military mobility planning via the EEA. Local Finance Signal: Liechtenstein’s PM told finance leaders stability is key as global change accelerates. Mobility Rules Watch: Thailand is rolling back its visa-free 60-day scheme to 30 days for most countries, tightening entry after security and overstaying concerns.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result.
Perspectify News
